Please login to the form below

Not currently logged in
Email:
Password:

AZ's phase III RA trial underway

AstraZeneca has announced the beginning of phase III clinical trial development for rheumatoid arthritis treatment fostamatinib

AstraZeneca (AZ) has announced the beginning of phase III clinical trial development for rheumatoid arthritis (RA) treatment fostamatinib.

The trial will study the effects of fostamatinib – developed as an oral syk inhibitor – in patients with previously inadequate response to disease-modifying anti-rheumatic drugs (DMARDs).

Syk is a form of tyrosine kinase protein that can lead to the inflammatory conditions of RA when functioning abnormally. Fostamatinib is designed to block the function of syk, halting progression of the disease.

Phase III development of the drug will see three trials assessing its efficacy and safety, including two 12-month studies examining the effect of fostamatinib on patients responding inadequately to DMARDs.

As published in the New England Journal of Medicine, a previous phase II programme demonstrated positive results for the drug, then known as R788, in RA patients who failed to respond adequately to current treatments.

Commenting on the development of fostamatinib, Anders Ekblom, AZ's executive vice president of global medicines development, said: "Patients with rheumatoid arthritis currently have limited treatment options after they stop responding adequately to DMARDs or anti-TNF therapy, and we are hopeful that fostamatinib may represent a novel alternative for patients to help manage their condition beyond this stage."

Fostamatinib was initially developed by Rigel Pharmaceuticals, with AZ purchasing rights to further develop and commercialise the drug in February 2010.

29th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics